Effectiveness of the modified catheterization technique in the percutaneous treatment of hepatic cystic echinococcosis: results in 183 patients.

BackgroundHepatic cystic echinococcosis (CE) is a major health concern, particularly in endemic regions. The modified catheterization technique (MoCaT) offers an effective option for the percutaneous treatment of hepatic CE.PurposeTo evaluate the effectiveness of MoCaT in the percutaneous treatment of all types of hepatic CE in 183 patients.Material and MethodsData from 183 patients who underwent percutaneous treatment using the MoCaT between February 2010 and April 2024 were retrospectively analyzed. Demographic data, cyst types, initial and final cyst volumes, complications, lengths of hospitalization, catheterization, and follow-up periods were documented for each patient.ResultsThis study included 183 patients with 211 hepatic hydatid cysts who were treated percutaneously with MoCaT. Among the 211 cysts, 20 (9.5%) were CE1, 37 (18%) were CE2, 23 (11%) were CE3a, 98 (46%) were CE3b, 16 (7.6%) were CE4, and 2 (0.9%) were CE5. In total, 15 (7%) patients presented with infected cyst cavities. No mortality was seen. A total of 29 (14%) major complications were observed. Recurrence was observed in 6 (3.85%) patients, and residual daughter vesicles remained in 1 (0.64%) patient. The mean follow-up period was 48.35 ± 36.42 months (range = 3-133 months). Mean volume reduction was 92.69%.ConclusionThe MoCaT is an effective, minimally invasive method with low morbidity and recurrence rates. In addition to its reported success in treating CE2 and CE3b cysts, we report that the MoCaT is also safe, reliable, and effective for the treatment of all types of hepatic CE.